Explore recent issues of Contract Pharma covering key industry trends.
Read the full digital version of our magazine online.
Stay informed! Subscribe to Contract Pharma for industry news and analysis.
Get the latest updates and breaking news from the pharmaceutical and biopharmaceutical industry.
Discover the newest partnerships and collaborations within the pharma sector.
Keep track of key executive moves and promotions in the pharma and biopharma industry.
Updates on the latest clinical trials and regulatory filings.
Stay informed with the latest financial reports and updates in the pharma industry.
Expert Q&A sessions addressing crucial topics in the pharmaceutical and biopharmaceutical world.
In-depth articles and features covering critical industry developments.
Access exclusive industry insights, interviews, and in-depth analysis.
Insights and analysis from industry experts on current pharma issues.
A one-on-one video interview between our editorial teams and industry leaders.
Listen to expert discussions and interviews in pharma and biopharma.
A detailed look at the leading US players in the global pharmaceutical and BioPharmaceutical industry.
Browse companies involved in pharmaceutical manufacturing and services.
Comprehensive company profiles featuring overviews, key statistics, services, and contact details.
A comprehensive glossary of terms used in the pharmaceutical and biopharmaceutical industry.
Watch in-depth videos featuring industry insights and developments.
Download in-depth eBooks covering various aspects of the pharma industry.
Access detailed whitepapers offering analysis on industry topics.
View and download brochures from companies in the pharmaceutical sector.
Explore content sponsored by industry leaders, providing valuable insights.
Stay updated with the latest press releases from pharma and biopharma companies.
Explore top companies showcasing innovative pharma solutions.
Meet the leaders driving innovation and collaboration.
Engage with sessions and panels on pharma’s key trends.
Hear from experts shaping the pharmaceutical industry.
Join online webinars discussing critical industry topics and trends.
A comprehensive calendar of key industry events around the globe.
Live coverage and updates from major pharma and biopharma shows.
Find advertising opportunities to reach your target audience with Contract Pharma.
Review the editorial standards and guidelines for content published on our site.
Understand how Contract Pharma handles your personal data.
View the terms and conditions for using the Contract Pharma website.
What are you searching for?
Earns EcoVadis Platinum Rating and validation of its emission reduction targets by the Science Based Targets initiative (SBTi).
January 21, 2026
By: Charlie Sternberg
Associate Editor
Vetter, a Contract Development and Manufacturing Organization (CDMO), has earned an EcoVadis Platinum rating and received validation of its emission reduction targets by the Science Based Targets initiative (SBTi). Both achievements highlight the company’s commitment to climate protection and responsible business practices.
This is the fourth consecutive year that Vetter has been recognized by the EcoVadis sustainability ranking, earning Platinum status for 2025 and placing itself among the top 1 percent of all rated companies globally.
The official validation of the emission reduction targets by the SBTi approves Vetter’s ambitious sustainability roadmap: by 2034, the CDMO aims to reduce absolute greenhouse gas emissions from Scope 1 and 2 by 58.8 percent (baseline 2021). These goals align with the Paris Agreement and represent one of the most rigorous standards for corporate climate action worldwide. The planned reductions will be achieved through a comprehensive mix of measures, including technical modernization of facilities and equipment, leveraging energy recovery potentials such as waste heat, and transitioning to lower-carbon energy sources–for example, replacing natural gas with biomethane.
“We are proud of the various steps we are taking to reduce our company’s carbon footprint,” said Managing Director Henryk Badack. “Both the validation by the SBTi and the Platinum rating from EcoVadis emphasize our strategic commitment to both people and planet and bring us one step closer to effective climate protection and to achieving overall sustainabilty goals.”
In June, Vetter began construction of its new clinical manufacturing site in Des Plaines.
Enter the destination URL
Or link to existing content
Enter your account email.
A verification code was sent to your email, Enter the 6-digit code sent to your mail.
Didn't get the code? Check your spam folder or resend code
Set a new password for signing in and accessing your data.
Your Password has been Updated !